Basic Information
|
|
Name: Dr. Obaro S. MICHAEL |
Faculty: BASIC CLINICAL SCIENCES |
|
Email:This email address is being protected from spambots. You need JavaScript enabled to view it. |
Department:Pharmacology and Therapeutics | |
|
Designation: Senior Lecturer |
||
|
Brief Biography: |
||
Resume
|
BIOGRAPHICAL SKETCH |
||||
|
NAME Dr. O.S. Michael |
POSITION TITLE Lecturer, Department of Pharmacology and Therapeutic, College of Medicine, University of Ibadan, Nigeria |
|||
|
EDUCATION/TRAINING |
||||
|
INSTITUTION AND LOCATION |
DEGREE |
MM/YY |
FIELD OF STUDY |
|
|
University of Ibadan, Nigeria |
Ph.D in view |
Ongoing |
Molecular Pharmacology |
|
|
University of Ibadan, Nigeria |
M.Sc |
Dec 2009 |
Molecular Pharmacology |
|
|
UCH, Ibadan (Residency Training) |
FMCP Nig |
May 2009 |
Clinical Pharmacology |
|
|
UDUS, Sok., Nigeria |
MBBS |
Feb 1998 |
Medicine / Surgery (undergraduate) |
|
Positions and Honors
Doctoral Student PG Sch. University of Ibadan Ongoing
Senior Registrar, Department of Clinical Pharmacology, UCH,2005 – 2008.
Registrar,Department of Clinical Pharmacology, UCH, 2002 - 2005
Research Physician, Malaria Research Group, UCH Ibadan, 2000-2002
NYSC Physician,Malaria Research Group, UCH, Ibadan, 1999 – 2000.
House Officer,Gwagwalada Sprecialist Hospital, Abuja,1999 – 2000.
Memberships/Honors
Fellow, National Postgraduate Medical College
Community Member, British Society of Pharmacologists
Member, American Society of Microbiologists
Member, Africa Malaria Clinical Trials Alliance
Member, NAFDAC National Pharmacovigilance Committee
Member Nigerian Medical Association
Reviewer and Editor, Journal of Biotechnology and Pharmaceutical Research
Reviewer, Journal of Public Health and Epidemiology
Reviewer, International Journal of Medicine and Medical Sciences
Researches
Research Support
- Antimalarial Drug Resistance Network in Nigeria (WHO ID A 20239) To develop markers of chloroquine resistance to antimalarial drug.2002 to 2008. Funding agency- WHO TDR, role- Trainee
- Identification of molecular determinants of drug resistance in Plasmodium falciparumfrom Southwest Nigeria. 2004 to date.Funding agency- EDCTP, role- co-Investigator
- Federal Ministry of Health-sponsored Antimalarial Drug Efficacy Testing (DTET) in Southwest zone of Nigeria. 2004 to date. Funding agency- Federal ministry of health, Role- Co-Investigator
- An open Label, Randomized trial of the therapeutic efficacy, safety and tolerance of co-packaged amodiaquine plus artesunate (DartTM) and co-formulated artesunate plus amodiaquine (CoarsucamTM) versus artemether plus lumefanthrine (CoartemTM) for the treatment of uncomplicated Plasmodium falciparummalaria in children. 2009-2010. Funding agency- SWIPHA, Role- co-Investigator
- A prospective study to assess Adverse Drug Reactions in patients with or without HIV-AIDS who are on treatment for Tuberculosis.2006. FMCP Project. Role- Investigator
Publications
Selected Peer-reviewed Publications
Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, Oduola AMJ, and Happi TC. Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malaria journal, 2010, 9;335
Falade CO, Nash O, Akingbola TS, Michael OS, Olojode F, Ademowo OG. Blood banking in a malaria endemic area: evaluating the problem posed by malaria parasitemias. Ann Trop Med Parasitol 2009, 103: 383-92.
Sowunmi A, Gbotosho GO, Okuboyejo T, Folarin O, Balogun S, Michael O. Therapeutic efficacy and effects of artesunate-mefloquine and Mefloquine alone on malaria-associated anemia in children with uncomplicated plasmodium falciparum malaria in South-West Nigeria. Am J Trop Med Hyg. 2009, 81; 979-86.
Falade CO, Michael OS, Oduola AM. Enhanced efficacy of amodiaquine and chlorpheniramine combination over amodiaquine alone in the treatment of acute uncomplicated plasmodium falciparum malaria in children. Med Princ Pract. 2008, 17: 197-201.
Contact Information
| Phone: 08056642410 | Address: | Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Facebook: Profile Link | LinkedIn: Profile Link | Twitter: Profile Link |
| Instagram: Profile Link | YouTube: Profile Link |
Pinterest: Profile Link
|